公司資料
AtriCure 股價、新聞與催化劑
- 股票代碼:
- ATRC
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
44.77 USD (+1.06%)
收盤價
最後更新: 2026年8月17日
1.31B USD
市值
股價為何變動
As of Aug 17, 2026, ATRC closed up 1.06% at $44.77. No new same-company headline was identified in the current news window.
公司概覽
Atrial Fibrillation Surgery
AtriCure develops medical devices and procedures for the surgical treatment of atrial fibrillation. Its products are used by cardiac surgeons to create controlled lesions that interrupt abnormal electrical pathways and restore a more regular heart rhythm.
Ablation Technologies
The Isolator Synergy Ablation System is FDA approved for persistent atrial fibrillation and anchors AtriCure’s surgical ablation portfolio. The company also offers the Hybrid AF Therapy, a minimally invasive approach for patients with long-standing persistent atrial fibrillation.
Adjacent Surgical Markets
AtriCure’s broader portfolio includes left atrial appendage management and post-operative pain-management products. These complementary technologies allow the company to serve multiple needs within cardiac and thoracic surgery using a common physician and hospital customer base.
未來催化劑
- AtriCure's catalysts are AF ablation adoption, left-atrial appendage management, and continued procedure growth in cardiac surgery. The company improves when its installed physician base keeps converting into repeatable use.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。